Evaluation of Biomonitoring Data from the CDC National Exposure Report in a Risk Assessment Context: Perspectives across Chemicals

Lesa L. Aylward, Christopher R. Kirman, Rita Schoeny, Christopher J. Portier, Sean M. Hays

Evaluation of Biomonitoring Data from the CDC National Exposure Report in a Risk Assessment Context: Perspectives across Chemicals

Lesa L. Aylward[1*], Christopher R. Kirman[2], Rita Schoeny[3], Christopher J. Portier[4], Sean M. Hays[5]

[1] Summit Toxicology, LLP, Falls Church, Virginia, USA

[2] Summit Toxicology, LLP, Orange Village, Ohio, USA

[3] Office of Research and Development, United States Environmental Protection Agency, Washington, District of Columbia, USA

[4] National Center for Environmental Health and Agency for Toxic Substances and Disease Registry, Atlanta, Georgia, USA

[5] Summit Toxicology, LLP, Lyons, Colorado, USA

[*] Corresponding author:

Lesa L. Aylward

Summit Toxicology, LLP

6343 Carolyn Drive

Falls Church, VA 22044 USA

+1 (703) 349-3515

laylward@summittoxicology.com

Running Title: Risk assessment review: NER biomonitoring data

Keywords: Biomonitoring; Biomonitoring Equivalents; blood; cancer risk; CDC National Exposure Report; hazard quotient; NHANES; risk assessment; urine

Disclaimer: The contents of this manuscript are solely the responsibility of the authors and do not necessarily reflect the views or policies of the US Environmental Protection Agency or the National Center for Environmental Health and Agency for Toxic Substances and Disease Registry.

Abbreviations:

ADI	Acceptable daily intake
ANSES	Agency for Food, Environmental and Occupational Health and Safety
ATSDR	Agency for Toxic Substances and Disease Registry
BE	Biomonitoring Equivalent
CDC	Centers for Disease Control and Prevention

DEHP   Di-2(ethylhexyl) phthalate

HBC   Human biomonitoring commission

HBM-I   Human biomonitoring value - I

HI   Hazard index

HQ   Hazard quotient

IPCS   International Programme on Chemical Safety

LOD   Limit of detection

MRL   Minimal risk level

NER   National Exposure Report

NHANES   National Health and Nutrition Examination Survey

NOAEL   No observed adverse effect level

RfC   Reference concentration

RfD   Reference dose

RSD   Risk-specific dose

TDI   Tolerable daily intake

THM   Trihalomethane

USEPA   United States Environmental Protection Agency

VOC   Volatile organic compound

Abstract

BACKGROUND: Biomonitoring data reported in the National Report on Human Exposure to Environmental Chemicals (National Exposure Report; NER) provide information on the presence and concentrations of more than 400 chemicals in human blood and urine. Biomonitoring Equivalents (BEs) and other risk assessment-based values now allow interpretation of these biomonitoring data in a public health risk context. OBJECTIVES: Compare the measured biomarker concentrations in the NER with BEs and similar risk assessment values to provide an across-chemical risk assessment perspective on the measured levels for approximately 130 analytes in the NER. METHODS: Available risk assessment-based biomarker screening values, including BEs and Human Biomonitoring-I (HBM-I) values from the German Human Biomonitoring Commission, were identified. Geometric mean and 95th percentile population biomarker concentrations from the NER were compared to the available screening values to generate chemical-specific hazard quotients (HQ) or cancer risk estimates. CONCLUSIONS: Most analytes in the NER show HQ values below 1; however, some (including acrylamide, dioxin-like chemicals, benzene, xylene, several metals, di-2(ethylhexyl)phthalate, and some legacy organochlorine pesticides) approach or exceed HQ values of 1 or cancer risks greater than 1×10^{-4} at the geometric mean or 95th percentile, suggesting exposure levels may exceed published human health benchmarks. This analysis provides for the first time a means for examining population biomonitoring data for multiple environmental chemicals in the context of the risk assessments for those chemicals. The results of these comparisons can be used to focus more detailed chemical-specific examination of the data and inform priorities for chemical risk management and research.

4

Introduction

Large population-representative biomonitoring studies such as the National Report on Human Exposure to Environmental Chemicals (CDC 2012) -- which we will refer to as the National Exposure Report (NER) -- and other national biomonitoring efforts such as those conducted in Canada and in Germany are providing valuable data on the prevalence and concentrations of chemicals in biological matrices such as blood or urine from individuals in the general population. These measured concentrations provide an integrated reflection of exposures that may occur via multiple routes and pathways. For this and other reasons, biomonitoring is increasingly being relied upon as a state-of-the-art tool for exposure assessment for environmental chemicals (Sexton et al. 2004). The NER provides unparalleled data on several hundred analytes in a representative sample of the US general population. These data are a potentially rich source of information for risk managers and researchers looking to identify and study chemical exposures in the general population.

Biomonitoring studies can establish exposure levels across a study population and provide a means to compare exposures across population groups by age, sex, ethnicity, or other demographic descriptors. Biomonitoring results can also be used to establish research priorities, to measure trends in exposure over time and to verify the efficacy of selected pollution controls and other public health policy actions. There are limitations in biomonitoring data in that they are generally single time point measures. Moreover, as noted by the Centers for Disease Control and Prevention (CDC), ''[T]he presence of a chemical does not imply disease. The levels or concentrations of the chemical are more important determinants of the relation to disease, when established in appropriate research studies, than the detection or presence of a chemical'' (CDC 2005).

The significance of the measured concentrations of chemicals in the context of existing toxicology data and risk assessments can be assessed if chemical-specific, biomonitoring-based risk assessment values are available. Such risk assessment values would ideally be based on robust datasets relating adverse effects to biomarker concentrations in human populations (e.g., the historical use of a "blood lead level of concern" by CDC and other organizations). However, development of such epidemiologically-based values is a resource- and time- intensive effort, and in practice, data to support such assessments exist for only a few chemicals. As an interim approach, the concept of Biomonitoring Equivalents (BEs) has been developed, and guidelines for the derivation and communication of these values have been published (Hays et al. 2007, 2008; LaKind et al. 2008).

A BE is defined as the concentration or range of concentrations of a chemical or its metabolites in a biological matrix (blood, urine, or other matrix) that is consistent with an existing non-cancer health-based exposure guidance value such as a Reference Dose (RfD) or Tolerable or Acceptable Daily Intake (TDI or ADI) or with a cancer-based exposure guidance value such as a risk-specific dose (e.g., the dose associated with a 1×10^{-4} cancer risk) (Hays et al. 2008a). BEs are intended to be used as screening tools to provide an assessment of which chemical biomarkers are present at levels below, near, or above concentrations consistent with existing risk assessments and exposure guidance values. BEs allow for the translation of conventional risk assessment guidance to evaluation of exposure information provided by biomonitoring data. Comparison of biomarker concentrations to the BE values can be used to guide the evaluation of multiple exposures in a population and to set priorities for research or reduction in exposures.

BE values have now been derived for approximately 90 compounds included in the NER

6

analyte list (Angerer et al. 2011; see Table 1). Public health risk-based values in terms of

biomarker concentrations for a number of additional analytes are available from several other

sources (including the German Human Biomonitoring Commission, reviewed in Angerer et al.

2011). This manuscript presents an initial examination of the broad range of chemicals included

in the NER, comparing the measured levels in the NER to the risk assessment-based BE values

as well as other risk assessment based biomarker values. These comparisons can be used to

inform decisions on prioritizing additional research and prioritizing national strategies to reduce

exposures. These can also be used to identify data needs to enable a fuller assessment of the

NER biomonitoring data in a health risk context.

Methods

NER biomonitoring data. Descriptive statistics for the NER biomonitoring data were

obtained from the CDC online summary tables (CDC 2012). The most recent available data

were selected for each analyte. For some analytes with previously-described dependence of

biomarker concentration on age (some persistent organochlorine compounds) or smoking status

(e.g. cadmium, acrylamide, benzene, toluene), simple descriptive statistics for population groups

(population weighted geometric mean, 95th percentile) were calculated from online data available

from the National Health and Nutrition Examination Survey (NHANES) (CDC 2012) using

STATA IC10 (Stata Corp., College Station, TX). Such population group analyses were

conducted where *a priori* information suggested relevance, but no attempt was made at a

comprehensive assessment of patterns by smoking or age across all the chemicals in the analysis.

For analysis of acrylamide and cadmium biomarkers, serum cotinine ≥ 10 ng/mL was assumed to

indicate that the individual was a smoker (Pirkle et al. 1996). For volatile organic compounds,

we used the analysis by smoking status presented in Kirman et al. (2012) based on the presence or absence of detectable serum 2,5-dimethylfuran.

Biomarker screening values. Chemical-specific, public health-based screening values for the evaluation of biomarker concentrations were identified from several sources. These included the following: BEs (reviewed in Angerer et al. 2011); Human Biomonitoring-I (HBM-I) values from the German Human Biomonitoring Commission (reviewed in Schulz et al. 2011); a blood concentration Reference Dose equivalent for methylmercury derived from the NAS (2000) report; and "critical concentrations" for polychlorinated biphenyl compounds recently set by the French Agency for Food, Environmental and Occupational Health and Safety (ANSES 2010). Where more than one screening value was available we selected one based on a hierarchy of preference. For example, BE values have been derived for bisphenol A based on multiple exposure guidance values such as an RfD from USEPA and a TDI set by the European Food Safety Authority. First preference was given to BE values corresponding to the USEPA RfD or RfC values as they comprise a large number of detailed, peer reviewed, publicly available assessments (USEPA 2012a); this was followed by the BE values corresponding to ATSDR Minimal Risk Levels (MRLs; ATSDR 2012). For VOCs, BE values corresponding to inhalation-based exposure guidance values were selected when available, followed by those corresponding to oral exposure guidance values when no inhalation-based value was available. For several compounds including dioxins, 2,4-dichlorophenoxyacetic acid, and six VOCs (see Table 2, chemicals with footnote "c"), new risk assessments have been published since the BE values were derived and published. For these chemicals, the BE values were updated to correspond to the revised risk assessments, and the new values are footnoted in the results tables.

For this analysis, a "screening" value is one that allows evaluation of biomonitoring data in the context of chemical risk assessments. BE values and other values used here are not screening values in the medical sense of the term.

The definitions and methods for derivation of BE and HBM-I values are reviewed in Angerer et al. (2011). In general, the identified screening values correspond to biomarker concentrations consistent with exposure levels previously deemed to be unlikely to result in adverse effects in the human population, including sensitive subgroups (e.g., see the USEPA definition of RfD at http://www.epa.gov/iris/help_gloss.htm#r; USEPA 2012b).

Risk assessment approaches. NER biomonitoring data were evaluated using the BE or other identified screening values in two ways. For BEs based on non-cancer endpoints (RfDs, MRLs, etc.), hazard quotients (HQ) were calculated:

$$HQ = \frac{[Biomarker]}{BE} \qquad [1]$$

HQ values near or above 1 provide an indication that exposure levels are near or above the exposure benchmark underlying the BE value.

BE values have been derived corresponding to risk-specific doses (BE_{RSD}) as well, and can be used in a parallel fashion to evaluate chemicals with slope factors. Risk-specific doses (RSDs) are estimates of the lifetime average daily exposure associated with a specified (cancer) risk level for a chemical. BE_{RSD} values provide an estimate of the lifetime steady-state blood concentration that would result from chronic exposure at those risk-specific doses (the same is true for BEs based on chronic RfDs and MRLs). Risks were estimated assuming linear extrapolation on the basis of biomarker concentrations above and below the BE_{RSD} value. For

highly persistent analytes, measured biomarker concentrations at a single point in time may provide a reasonably accurate surrogate for long-term average concentrations and, therefore, potential risks (according to current risk assessments) for individuals. However, for highly transient analytes, conclusions regarding both non-cancer and lifetime cancer risks based on samples from a single time point in blood or urine of individuals are much more uncertain (Aylward et al. 2012).

Some compounds in the NER analyte list are detected in few or no individuals in the sampled population. For those cases in which an analyte was below the limit of detection (LOD) at the geometric mean or 95th percentile in the NER dataset, the LOD was compared to the BE values in order to assess whether the LOD is sufficiently sensitive to provide information that is relevant in a risk assessment context. For instance, for compounds with LOD values lower than the BE, a lack of detected analytes in the population indicates that exposures in the general population are below the risk assessment-derived exposure guidance values. This information can be useful in assessing whether future biomonitoring studies (with improved detection limits) are likely to be of increased value in a risk assessment context, or whether the LOD is sufficiently sensitive to provide relevant public health risk assessment conclusions for the analyte.

Results

The descriptive statistics for the NER data and the identified biomarker-based risk assessment values based on non-cancer exposure guidance values are summarized in Tables 1 and 2. Chemical-specific biomarker-based screening values were identified for the evaluation of 130 NER analytes (including 29 dioxin, furan, and coplanar PCBs and 35 non-dioxin-like PCBs).

A number of chemical groups that are included in the NHANES analyte list have few or no screening values available for assessment of biomarker concentrations. These include the perfluorinated compounds, the phytoestrogens, most of the polybrominated diphenylethers, most of the pesticide analytes including the organophosphates, the parabens, and many of the metals.

Calculated HQ values based on non-cancer endpoints are presented in Figure 1 (non-VOCs) and Figure 2 (VOCs). Among the non-VOCs, HQ values approached or exceeded 1 at the population 95th percentiles for acrylamide in smokers, di(2-ethylhexyl)phthalate (DEHP), dioxins, cadmium in smokers, and inorganic arsenic. Of these, DEHP and inorganic arsenic have short half-lives in the body and thus are expected to exhibit substantial intra-individual variability. Thus, upper and lower percentiles of the biomarker concentration distribution for these two chemicals may not be informative of long-term average biomarker concentrations for individuals. That is, spot samples at the upper end of the distribution may represent samples collected closer in time to exposure events rather than necessarily indicating a higher absolute exposure level. Similarly, spot samples with concentrations at the lower end of the distribution may represent samples taken at longer times since exposure events rather than indicating a lower absolute exposure level (Aylward et al. 2012). Central tendency concentrations, however, are still likely to be representative of longer-term average exposure levels for the general population. The levels measured for acrylamide, dioxins and cadmium are expected to be more stable, with little intra-individual variability. HQ values did not exceed 1 at the geometric mean biomarker concentration for any analyte. HQ values between 0.1 and 1 were observed for a number of these more stable compounds at both the geometric mean and the 95th percentile.

Among VOCs, 95th percentile HQs exceeded 1 for benzene in smokers, for xylenes in both smokers and non-smokers, and for 1,4-dichlorobenzene (Figure 2). As noted in previous

11

evaluations of the VOCs (Kirman et al. 2012), these compounds are rapidly metabolized and the measured biomarkers tend to be relatively transient. Upper and lower percentiles of the biomarker concentration distribution may not be informative of daily or longer-term average biomarker concentrations, with the possible exception of smokers. Central tendency measures such as geometric means may be more informative of typical average biomarker concentrations in the population. At the geometric mean, no VOC analytes exceeded an HQ of 1.

Many VOC analytes were detected in less than 5% of the sampled population (open symbols, right half of Figure 2). For most of these analytes, the LOD was at or below the BE, suggesting that from a risk assessment perspective, the analyses were sufficiently sensitive to provide useful information. In this context, the lack of detectable concentrations suggest that exposures in the general population are typically well below levels associated with risk assessment-based exposure benchmarks. This information can be considered as part of an assessment of the value of dedicating resources (larger biological sample volumes or additional methods development) to attaining lower LODs for these analytes.

Cancer risk levels corresponding to the geometric mean and 95th percentile NER biomarker concentrations are presented in Figure 3 for the 13 analytes with both cancer risk-based screening values and frequent detections (>60%) in the NER datasets. Cancer risk level targets in US regulatory arenas generally focus on a range of 10^{-6} to 10^{-4}, although this range is flexible depending on the context (offsetting benefits, widespread vs. infrequent exposures, etc.). Cancer risk estimates corresponding to the 95th percentile biomarker concentrations for 12 of the 13 compounds with available cancer-based screening values exceed the 10^{-6} cancer risk level and cancer risk estimates corresponding to the geometric mean biomarker concentrations for 8 of these compounds approach or exceed the 10^{-4} cancer risk level (see Figure 3).

Discussion

This review provides the first broad examination of the NER biomonitoring datasets in a health risk context across a broad range of the included analytes. Biomonitoring-based screening values addressing 130 of the NER analytes were identified, allowing the measured concentrations of these biomarkers in the US population to be evaluated in terms of risk assessment-based screening values. Hazard quotients exceeding 1 were observed at the 95th percentile for a number of analytes, suggesting exposures in portions of the US population may exceed risk assessment-based exposure guidance values for these compounds, at least intermittently. Evaluation of the health risk implications of HQ values in excess of 1 requires consideration of chemical-specific information on the basis for the underlying exposure guidance values, the uncertainty factors applied in the derivation of those values, the robustness of the health effects database, and other factors. Some of the chemicals with higher HQ values are compounds that are intentionally manufactured and used in products or released to the environment (e.g., 1,4-dichlorobenzene and DEHP). However, others are present in the environment primarily due to formation as unintentional byproducts of combustion or other reactions (e.g., dioxin-like chemicals and acrylamide) or at least in part due to their natural occurrence (e.g., arsenic and mercury compounds).

Similarly, biomarker concentrations approached or exceeded concentrations consistent with cancer risk levels exceeding 1×10^{-6} for a number of analytes. However, interpretation of risks for cancer should be made cautiously because the risk-specific BE values presented here are estimates of the steady-state concentration associated with lifetime average daily doses at the risk-specific dose.

13

Comparison of measured biomarker concentrations to BE values incorporates an implicit assumption that the biomarker concentrations represent chronic average biomarker concentrations for the individuals sampled. While this may be a reasonable assumption for highly persistent compounds, spot sample concentrations of more transient compounds may not provide reliable surrogates for long-term or lifetime average biomarker concentration in individuals (Aylward et al. 2012). For such chemicals, extremes at both ends of the population distribution of biomarker concentrations may be more unreliable as indicators of long-term exposure levels for individuals, while central tendency measures such as geometric mean calculations may be more informative of longer-term average biomarker concentrations on a population basis. The results presented here indicate that, even at the geometric mean biomarker concentrations, cancer risk levels are in excess of $1x10^{-6}$ for several analytes, and, for some analytes, exceed $1x10^{-3}$.

The chemicals currently on the NER analyte list have been selected for inclusion in the survey for a variety of reasons. Many of the chemicals have traditionally been of concern due to known toxic potency (e.g., the dioxin-like chemicals), high industrial volume (e.g., selected solvents such as toluene), potential for bioaccumulation (e.g., persistent organochlorine insecticides), potential for widespread exposure (e.g. phthalates, trihalomethanes), or combinations of these reasons. Given this combination of selection criteria, the presence of some chemicals near or above the risk assessment-based screening criteria is not unexpected. And, while biomonitoring data for a number of chemicals suggest exposure levels approaching or exceeding the risk assessment-based benchmarks for some of the population, it is also important to note that for most of the chemicals evaluated here the HQ values are below 1 for all or the majority of the population.

Combined exposures. A major issue of interest when the levels of multiple analytes are examined is the importance of co-occurrence and the potential for combined exposure and toxicity. While HQ values for individual analytes might not exceed 1 in an individual or in the population, thereby suggesting that adverse effects are unlikely, the presence of multiple chemicals in individuals raises the question of whether interactions (either additive, synergistic, or antagonistic) occur that could result in adverse effects even when individual analytes remain below an HQ value of 1. Considerations relevant to assessment of combined exposures to chemicals are discussed in the recent International Programme on Chemical Safety (IPCS) *Framework for Assessment of Combined Exposures* (Meek et al. 2011). Factors to be evaluated when considering a combined exposure and risk assessment include whether the chemicals have a common mechanism or mode of action, common toxicity targets, are expected to co-occur, and other considerations.

The NER datasets provide a nearly unprecedented opportunity to examine co-occurrence of chemicals in biological matrices, reflecting concurrent exposures in the population. However, the full set of analytes in the NER program is not measured in any individual. Instead, due to limitations in the volume of biological samples (blood, urine) available, analyses for specific analyte groups are generally conducted on 1/3rd subsets of the full NER sample in a given cycle. This still results in multiple chemical groups being measured in many individuals, so it is possible to examine co-exposure to selected sets of chemicals in individuals in the dataset. Figure 4 presents a schematic showing the distribution of analytes among the NHANES subsets from the 2003-2004 cycle.

Combined exposure assessment may be of particular interest for certain groups of chemicals if the chemicals produce similar pathology or if they act on a similar mechanistic

pathway or toxicological endpoint. For example, the current USEPA non-cancer assessments for

the chlorinated and brominated trihalomethanes (THMs) are based on similar liver pathology as

the most sensitive endpoint (USEPA 2012a; reviewed in Aylward et al. 2008b). THMs are

believed to produce liver toxicity through a similar mode of action, and combined exposure to

these chemicals is likely to occur. Under these conditions, it may be appropriate to assess the

combined exposures using a hazard index (HI) approach, which assumes dose addition. Thus, for

each individual in the NHANES dataset, a THM hazard index was also calculated, summing the

chemical-specific HQs across the four THM compounds (i=1 to 4):

$$HI = \sum_{i=1}^{4} \frac{[THM_i]}{BE_{RfD\_i}}$$ [2]

For THM compounds in the 2003-2004 NER cycle, HIs for combined exposure to THM

compounds (calculated on an individual-by-individual basis) did not exceed 1 at the 95th

percentile (Figure 5; see also, LaKind et al. 2010).

Data gaps and limitations. As discussed above, a significant number of the chemical

groups in the NER analyte list have few or no available BEs or other screening values, which

limits the overall assessment of the full dataset from a risk assessment perspective. Development

of additional screening values covering a greater proportion of the NER analyte list, either

through direct epidemiological studies linking alterations in health endpoints to biomarker

concentrations, or through derivation of additional biomarker concentrations corresponding to

toxicity-based exposure guidance values (as in the Biomonitoring Equivalents framework) would

be useful in broadening the perspectives and utility of the evaluation methods presented here.

This may be challenging due to several factors: limited data on pharmacokinetics allowing

translation of external to internal exposure levels; the inclusion of non-specific biomarkers,

including degrades or metabolites that may appear in biological matrices due to direct exposure in the environment; and a lack of existing risk assessments or method for interpreting hazards of exposure (e.g., phytoestrogens). For some chemicals, there are additional limitations in the ability to assess the NER data because of the limited analytical sensitivity relative to population exposures (e.g., for metabolites of inorganic arsenic).

Additional uncertainties include chemical-specific issues. For example, dioxin concentrations in serum are routinely expressed in terms of dioxin "toxicity equivalents"; however, the relative potency estimates used for these calculations are specifically designed to estimate toxicity of mixtures on an intake basis, not on a tissue or body concentration basis, and differences in congener pharmacokinetics may result in inaccuracies in the serum-based TEQ estimates (van den Berg et al. 2006; USEPA 2012c). For bioaccumulative compounds, in general, lifetime average daily exposure at a given RSD or RfD would be expected to result in an age-dependent accumulation of the biomarker, and thus, consideration of age and accumulation is important.

Finally, as discussed above, the BE values are estimates of biomarker concentrations consistent with specific existing risk assessment derived exposure guidance values such as RfDs and MRLs; reliance on exposure guidance values other than those selected in this analysis could result in different BE values and estimated HQ or cancer risk estimates. Such exposure guidance values are the result of a risk assessment process that often involves extrapolation of toxicity data from laboratory animals to humans and the application of uncertainty factors to account for possible differences between animals and humans and among individuals in the human population, and these values are exposure route-specific. The BE values rely upon available toxicokinetic data to estimate corresponding steady-state biomarker concentrations, with

17

attendant uncertainties. Biomonitoring data often reflect multiple exposure routes and pathways that may or may not correspond to the exposure routes assumed in the underlying risk assessment, and the data reflect concentrations at a point in time that may be more or less representative of long term average concentrations, depending upon the chemical and exposure pathways. These uncertainties and complexities are important considerations in the examination and interpretation of the results presented in this analysis and should be incorporated in more detailed examination of the biomarker data and assessment of potential health risks on a chemical-specific basis.

Conclusions

The exposure data provided by the NER biomonitoring program are unique in terms of providing a cross-chemical assessment of the U.S. population's exposures to chemicals. Many approaches to evaluating and using these data for public health research are possible. This approach, in which these data are assessed in comparison to the available BE values and related health risk-based screening values, provides for the first time a means for examining population exposures to multiple environmental chemicals in the context of the risk assessments for those chemicals. This evaluation allows, for the chemicals included, a comparative analysis that can assist risk managers in prioritization of chemicals for more detailed chemical-specific evaluation and risk assessment follow-up. Such activities may include exposure pathway studies, detailed evaluation of underlying toxicological or risk assessment data and uncertainty factors included in the risk assessment process, and active steps to identify exposure mitigation strategies where appropriate. The value of the data will increase as BE values or other health risk-based

screening values are developed for additional analytes, which will allow expansion of the subset

of NER analytes that can be placed into this context.

References

Agence nationale de securite sanitaire Alimentation Environnement Travail (ANSES). 2010. Opinion of the French Food Safety Agency on interpreting the health impact of PCB concentration levels in the French population. Available: http://www.anses.fr/Documents/RCCP2008sa0053EN.pdf [Accessed 4 January 2012].

Agency for Toxic Substances and Disease Registry (ATSDR). 2012. Minimal Risk Levels (MRLs) for Hazardous Substances. Available: http://www.atsdr.cdc.gov/mrls/mrllist.asp [accessed March 3 2012].

Angerer J, Aylward LL, Hays SM, Heinzow B, Wilhelm M. 2011. Human biomonitoring assessment values: approaches and data requirements. Int J Hyg Environ Health 214(5):348-360.

Aylward LL, Barton HA, Hays SM. 2008a. Biomonitoring Equivalents (BE) dossier for toluene (CAS No. 108-88-3). Regul Toxicol Pharmacol 51(3 Suppl):S27-36.

Aylward LL, Hays SM. 2008. Biomonitoring Equivalents (BE) dossier for 2,4-dichlorophenoxyacetic acid (2,4-D) (CAS No. 94-75-7). Regul Toxicol Pharmacol 51(3 Suppl):S37-48.

Aylward LL, Hays SM, Gagne M, Krishnan K. 2009a. Derivation of Biomonitoring Equivalents for di-n-butyl phthalate (DBP), benzylbutyl phthalate (BzBP), and diethyl phthalate (DEP). Regul Toxicol Pharmacol 55(3):259-267.

Aylward LL, Hays SM, Gagne M, Krishnan K. 2009b. Derivation of Biomonitoring Equivalents for di(2-ethylhexyl)phthalate (CAS No. 117-81-7). Regul Toxicol Pharmacol 55(3):249-258.

Aylward LL, Hays SM, Gagne M, Nong A, Krishnan K. 2010a. Biomonitoring equivalents for hexachlorobenzene. Regul Toxicol Pharmacol 58(1):25-32.

Aylward LL, Kirman CR, Adgate, JL, McKenzie LM, Hays SM. 2012. Interpreting variability in population biomonitoring data: Role of elimination kinetics. J. Exp. Sci. Environ. Epidemiol. 22(4):398-408

Aylward LL, Kirman CR, Blount BC, Hays SM. 2010b. Chemical-specific screening criteria for interpretation of biomonitoring data for volatile organic compounds (VOCs)--application of steady-state PBPK model solutions. Regul Toxicol Pharmacol 58(1):33-44.

Aylward LL, Krishnan K, Kirman CR, Nong A, Hays SM. 2011. Biomonitoring equivalents for deltamethrin. Regul Toxicol Pharmacol 60(2):189-199.

Aylward LL, LaKind JS, Hays SM. 2008b. Biomonitoring Equivalents (BE) dossier for trihalomethanes. Regul Toxicol Pharmacol 51(3 Suppl):S68-77.

Centers for Disease Control and Prevention (CDC). 2005. Third National Report on Human Exposure to Environmental Chemicals. Department of Health and Human Services. Atlanta, GA.

Centers for Disease Control and Prevention (CDC). 2012. National Report on Human Exposure to Environmental Chemicals - Explore the Fourth Report and Updated Tables. Available: http://www.cdc.gov/exposurereport/data_tables/index.html#DataTablesByChemicalGroup [Accessed 4 January 2012].

Consumer Product Safety Commission (CPSC) 2001. Report to the U.S. Consumer Product Safety Commission by the Chronic Hazard Advisory Panel On Diisononyl Phthalate (DINP) June 2001 US. Consumer Product Safety Commission. Directorate for Health Sciences, Bethesda, MD 20814.

German Human Biomonitoring Commission. 2012. Human Biomonitoring Values. Available: http://www.umweltdaten.de/gesundheit-e/monitor/tab-hbm-values.pdf [Accessed 4 January 2012].

Hays SM, Aylward LL. 2008. Biomonitoring Equivalents (BE) dossier for acrylamide (AA) (CAS No. 79-06-1). Regul Toxicol Pharmacol 51(3 Suppl):S57-67.

Hays SM, Aylward LL, Gagne M, Krishnan K. 2009. Derivation of Biomonitoring Equivalents for cyfluthrin. Regul Toxicol Pharmacol 55(3):268-275.

Hays SM, Aylward LL, Gagne M, Nong A, Krishnan K. 2010. Biomonitoring equivalents for inorganic arsenic. Regul Toxicol Pharmacol 58(1):1-9.

Hays SM, Aylward LL, Kirman CR, Krishnan K, Nong A. 2011. Biomonitoring equivalents for di-isononyl phthalate (DINP). Regul Toxicol Pharmacol 60(2):181-188.

Hays SM, Aylward LL, LaKind JS, Bartels MJ, Barton HA, Boogaard PJ, et al. 2008a. Guidelines for the derivation of Biomonitoring Equivalents: report from the Biomonitoring Equivalents Expert Workshop. Regul Toxicol Pharmacol 51(3 Suppl):S4-15.

Hays SM, Becker RA, Leung HW, Aylward LL, Pyatt DW. 2007. Biomonitoring equivalents: a

screening approach for interpreting biomonitoring results from a public health risk
perspective. Regul Toxicol Pharmacol 47(1):96-109.

Hays SM, Nordberg M, Yager JW, Aylward LL. 2008b. Biomonitoring Equivalents (BE) dossier
for cadmium (Cd) (CAS No. 7440-43-9). Regul Toxicol Pharmacol 51(3 Suppl):S49-56.

Hays SM, Pyatt DW, Kirman CR, Aylward LL. 2012. Biomonitoring Equivalents for benzene.
Regul Toxicol Pharmacol. 62(1):62-73.

Kirman CR, Aylward LL, Blount BC, Pyatt DW, Hays SM. 2012. Evaluation of NHANES
biomonitoring data for volatile organic chemicals in blood: Application of chemical-specific
screening criteria. J Expo Sci Environ Epidemiol 22(1):24-34.

Kirman CR, Aylward LL, Hays SM, Krishnan K, Nong A. 2011. Biomonitoring equivalents for
DDT/DDE. Regul Toxicol Pharmacol 60(2):172-180.

Krishnan K, Adamou T, Aylward LL, Hays SM, Kirman CR, Nong A. 2011. Biomonitoring
equivalents for 2,2',4,4',5-pentabromodiphenylether (PBDE-99). Regul Toxicol Pharmacol
60(2):165-171.

Krishnan K, Gagne M, Nong A, Aylward LL, Hays SM. 2010a. Biomonitoring Equivalents for
bisphenol A (BPA). Regul Toxicol Pharmacol 58(1):18-24.

Krishnan K, Gagne M, Nong A, Aylward LL, Hays SM. 2010b. Biomonitoring Equivalents for
triclosan. Regul Toxicol Pharmacol 58(1):10-17.

LaKind JS, Aylward LL, Brunk C, DiZio S, Dourson M, Goldstein DA, et al. 2008. Guidelines
for the communication of Biomonitoring Equivalents: report from the Biomonitoring
Equivalents Expert Workshop. Regul Toxicol Pharmacol 51(3 Suppl):S16-26.

LaKind JS, Naiman DQ, Hays SM, Aylward LL, Blount BC. 2010. Public health interpretation
of trihalomethane blood levels in the United States: NHANES 1999-2004. J Expo Sci
Environ Epidemiol 20(3):255-262.

Meek ME, Boobis AR, Crofton KM, Heinemeyer G, Raaij MV, Vickers C. 2011. Risk
assessment of combined exposure to multiple chemicals: A WHO/IPCS framework. Regul
Toxicol Pharmacol. 60(2, Suppl. 1):S1-S14.

National Academy of Sciences (NAS). 2000. Toxicological Effects of Methylmercury.
Washington, DC: National Academy Press.

Patterson DG, Jr., Wong LY, Turner WE, Caudill SP, Dipietro ES, McClure PC, et al. 2009.

Levels in the U.S. population of those persistent organic pollutants (2003-2004) included in the Stockholm Convention or in other long range transboundary air pollution agreements. Environ Sci Technol 43(4):1211-1218.

Pirkle JL, Flegal KM, Bernert JT, Brody DJ, Etzel RA, Maurer KR.1996. Exposure of the U.S. population to environmental tobacco smoke: the Third National Health and Nutrition Examination Survey, 1988-1991. J. Am. Med. Assoc. 275:1233–40

Schulz C, Wilhelm M, Heudorf U, Kolossa-Gehring M. 2011. Update of the reference and HBM values derived by the German Human Biomonitoring Commission. Int J Hyg Environ Health 215(1):26-35.

Sexton K, Needham LL, Pirkle JL. 2004. Human biomonitoring of environmental chemicals. American Scientist 92:38-45.

United States Environmental Protection Agency (USEPA) 2002. Cyfluthrin: pesticide tolerance. Federal Register 67, 60976–60991.

United States Environmental Protection Agency (USEPA) 2010. Deltamethrin. Human Health Assessment Scoping Document in Support of Registration Review. EPA-HQ-OPP-2009-0637-0004. Office of Prevention, Pesticides, and Toxic Substances.

United States Environmental Protection Agency (USEPA), 2011. Memorandum. 2,4-D Petition for the Establishment of a New Formulation of 2,4-D Choline on Herbicide Tolerant Field Corn Containing the Aryloxyalkonate Dioxygenase-1 (ADD-1) Gene, October 27, 2011.

United States Environmental Protection Agency (USEPA). 2012a. Integrated Risk Information System (IRIS). Available: http://www.epa.gov/IRIS/ [accessed March 3, 2012].

United States Environmental Protection Agency (USEPA). 2012b. Integrated Risk Information System (IRIS) Glossary. Available: http://www.epa.gov/iris/help_gloss.htm#r. [accessed September 6, 2012].

United States Environmental Protection Agency (USEPA). 2012c. EPA's Reanalysis of Key Issues Related to Dioxin Toxicity and Response to NAS Comments, Volume 1 (CAS No. 1746-01-6) In Support of Summary Information on the Integrated Risk Information System (IRIS). EPA/600/R-10/038F, February 2012. Available: http://www.epa.gov/iris/supdocs/dioxinv1sup.pdf [accessed September 6, 2012].

Van den Berg M, Birnbaum LS, Denison M, De Vito M, Farland W, Feeley M, et al. 2006. The
2005 World Health Organization reevaluation of human and mammalian toxic equivalency
factors for dioxins and dioxin-like compounds. Toxicol Sci. 93:223-41.

Table 1: Risk assessment exposure guidance values (with year of derivation), corresponding screening Biomonitoring Equivalents (BE), and NER geometric means (GM) and 95th percentiles for analytes other than volatile organic compounds (VOCs; see Table 2). Geometric means and 95th percentiles are reported as point estimates; confidence limits on these estimates are available in the NER.

Analyte (Parent compound, if different)(NHANES cycle)	Exposure Guidance Values[a]		Corresponding BE or other biomarker screening value	Biomarker Units and Matrix	Notes	NER Data	
	Type, source, yr	Value				GM	95th %ile
Acrylamide hemoglobin adducts (acrylamide) (03-04)	RfD, USEPA, 2010	2E-03 mg/kg-d	190	pmol/g hemoglobin	b		
Non-smokers						49.9	89.6
Smokers						109.9	274
Bisphenol A (07-08)	RfD, USEPA, 1993	0.05 mg/kg-d	2000	ug/L urine	c	2.08	13
Triclosan (07-08)	RfD, USEPA, 2008	0.3 mg/kg-d	6400	ug/L urine	d	15.3	494
Pentachlorophenol (01-02)	HBM-I, German HBC, 1997		25	ug/L urine	e	<LOD (0.5)	1.94
Phthalates (07-08)							
Mono-ethylphthalate (Diethyl phthalate)	RfD, USEPA, 1993	0.8 mg/kg-d	18,000	ug/L urine	f	137	1790
Mono-n-butyl phthalate (Dibutyl phthalate)	RfD, USEPA, 1990	0.1 mg/kg-d	2,700	ug/L urine	f	18.9	110
Mono-benzylphthalate (Benzyl butyl phthalate)	RfD, USEPA, 1993	0.2 mg/kg-d	3,800	ug/L urine	f	10	81.4
Sum of 4 metabolites of DEHP	RfD, USEPA, 1991	0.02 mg/kg-d	400	ug/L urine	g	96.5	1019
Mono-carboxyoctylphthalate (Di-isononylphthalate)	ADI, CPSC, 2001	0.12 mg/kg-d	390	ug/L urine	h	6.8	63
Persistent organohalogen compounds (03-04)							
Hexachlorobenzene	MRL, ATSDR, 2002	5E-04 mg/kg-d	47	ng/g serum lipid	i	15.2	28.9
DDT+DDE (03-04)	RfD, USEPA, 1996	5E-04 mg/kg-d	5000	ng/g serum lipid	j		
Ages 12-19						99[k]	529
20-39						141[k]	694
40-59						285[k]	1742
60+						565[k]	3980

Table 1 (continued)

Analyte (Parent compound, if different)(NHANES cycle)	Exposure Guidance Values[a]		Corresponding BE or other biomarker screening value	Biomarker Units and Matrix	Notes	NER Data	
	Type, source, yr	Value				GM	95th %ile
Dioxin TEQ (29 dioxin, furan, and coplanar PCB compounds) (03-04)	RfD, USEPA, 2011	0.7 pg/kg-d	Variable by age due to accumulation	pg/g serum lipid	l	<LOD (variable)	37.8
Ages 12-19			15				14
20-39			21				18.7
40-59			21				32
60+			21				63.2
Summed PCBs (35 congeners) (03-04)	"Critical concentrations" ANSES, 2010	NA	700 (infants, children, women of childbearing age); 1800 (other adults)	ng/g serum lipid	m		
Ages 12-19			700			54.4	139
20-39			700			79.2	226.5
40-59			1800			186.4	470.7
60+			1800			347.3	929.4
PBDE 99	RfD, USEPA, 2008	1E-04 mg/kg-d	520	ng/g serum lipids	n	<LOD (variable)	42.2
Metals							
Cadmium (03-04)	RfD, USEPA, 1994	5E-04 mg/kg-d	1.5	ug/L urine	o		
Non-smokers						0.2	0.9
Smokers						0.3	1.6
Sum, DMA + MMA (Arsenic, inorganic) (09-10)	RfD, USEPA, 1993	3E-04 mg/kg-d	5.8	ug/L urine	p	4.7	18.9
Mercury (07-08)	NAS Benchmark concentration assessment	NA	5.8	ug/L blood	q	0.77	4.64
Thallium (07-08)	HBM-I, German HBC, 2011	NA	5	ug/L urine	e	0.146	0.4

Table 1 (continued)

Analyte (Parent compound, if different)(NHANES cycle)	Exposure Guidance Values[a]		Corresponding BE or other biomarker screening value	Biomarker Units and Matrix	Notes	NER Data	
	Type, source, yr	Value				GM	95th %ile
Current Use Pesticides (01-02)							
2,4-Dichlorophenoxyacetic acid	RfD, USEPA, 2011	0.05 mg/kg-d	2,000	ug/L urine	r	<LOD (0.2)	1.27
Cis-3-(2,2-Dibromovinyl)-2,2-dimethylcyclopropane carboxylic acid (Deltamethrin)	RfD, USEPA, 2010	0.01 mg/kg-d (adults)	50	ug/L urine	s	<LOD (0.1)	<LOD (0.1)
4-Fluoro-3-phenoxy-benzoic acid (Cyfluthrin)	RfD, USEPA, 2002	0.024 mg/kg-d	240	ug/L urine	t	<LOD (0.2)	<LOD (0.2)

GM, geometric mean; RfD, Reference dose; MRL, minimal risk level; ADI, acceptable daily intake; DEHP, di-2(ethylhexylphthalate); LOD, limit of detection; NA, not applicable.

Notes: a: All EPA exposure guidance values from IRIS (USEPA 2012a) unless otherwise noted (see Notes column); b: Derived based on methods described in Hays and Aylward (2008) with updated USEPA RfD value; c: Krishnan et al. 2010a; d: Krishnan et al. 2010b; e: German HBC (2012), derived from occupational biomonitoring data- no exposure guidance value was derived; f: Aylward et al. 2009a; g: Aylward et al. 2009b; h: ADI from CPSC (2001); BE derivation in Hays et al. 2011; i: MRL from ATSDR (2012), BE derivation presented in Aylward et al. 2010a; j: Kirman et al. 2011; k: Medians; l: Based on USEPA (2012c) RfD for dioxin as based on neonatal thyroid hormone alterations. Serum lipid concentrations associated with chronic intake at the RfD were modeled using the USEPA (2012c) approach. Identification of appropriate BE values for children under age 12 would require additional modeling and considerations. Age-specific NER concentration data as reported by Patterson et al. (2009). m: Critical concentrations from ANSES (2010). Age-specific NER concentration data as reported by Patterson et al. (2009); n: Krishnan et al. 2011; o: Hays et al. 2008b; p: Hays et al. (2010; DMA+MMA only due to low detection rates for inorganic arsenic species); q: NAS 2000- benchmark concentration in blood divided by UF of 10; r: RfD updated November, 2011, by USEPA Office of Pesticide Programs (USEPA 2011). BE based on Aylward and Hays (2008), but reflecting updated RfD, which was increased by a factor of 10 due to removal of the 10-fold uncertainty factor related to database uncertainties. s: RfD as described in USEPA (2010); BE derivation presented in Aylward et al. 2011; t: RfD as described in USEPA (2002); BE derivation presented in Hays et al. 2009.

Table 2: Risk assessment exposure guidance values (with year of derivation), corresponding screening Biomonitoring Equivalents (BE), and NHANES data for volatile organic compounds (VOCs) from the 2003-2004 cycle. BE values corresponding to inhalation expoure guidance values were used where available; when missing, BE values corresponding to oral exposure guidance values were selected. Point estimates for geometric mean and 95th percentiles are presented; confidence intervals on these statistics are available in the NER.

Chemical	Exposure Guidance Values[a] Type, source, year	Value	Corresponding BE Value, μg/L whole blood	Note	NER 2003-2004 Data, μg/L whole blood GM	95%-ile
Benzene	RfC, USEPA, 2003	0.03 mg/m^3	0.15	b		
Smokers					0.136	0.44
Nonsmokers					<LOD (0.024)	0.06
Ethylbenzene	MRL, ATSDR 2010	0.25 mg/m^3	1	c		
Smokers					0.067	0.16
Nonsmokers					0.028	0.071
Styrene	RfC, USEPA, 1993	1 mg/m^3	3	c		
Smokers					0.068	0.18
Nonsmokers					<LOD (0.03)	0.068
Toluene	RfC, USEPA, 2005	5 mg/m^3	20	d		
Smokers					0.324	0.99
Nonsmokers					0.082	0.34
Xylenes	RfC, USEPA, 2003	0.1 mg/m^3	0.3	c		
Smokers					0.261	0.6
Nonsmokers					0.161	0.4
Carbon tetrachloride	RfC, USEPA, 2010	0.1 mg/m^3	0.19	e	<LOD (0.005)	<LOD (0.005)
Chlorobenzene	RfD, USEPA, 1993	0.02 mg/kg-d	0.2	c	<LOD (0.011)	<LOD (0.011)
Dibromo-3-chloropropane, 1,2-	RfC, USEPA, 1991	0.0002 mg/m^3	0.001	c	<LOD (0.1)	<LOD (0.1)
Dichlorobenzene, 1,2-	RfD, USEPA, 1991	0.09 mg/kg-d	0.7	c	<LOD (0.1)	<LOD (0.1)
Dichlorobenzene, 1,4-	RfC, USEPA, 1996	0.8 mg/m^3	3	c	0.194	3.3
Dichloroethene, 1,1-	RfC, USEPA, 2002	0.2 mg/m^3	0.3	c	<LOD (0.009)	<LOD (0.009)
Dichloroethene, cis-1,2-	RfD, USEPA, 2010	0.002 mg/kg-d	0.034	e	<LOD (0.01)	<LOD (0.01)
Dichloroethene, trans-1,2-	RfD, USEPA, 2010	0.02 mg/kg-d	0.07	c	<LOD (0.01)	<LOD (0.01)
Dichloromethane	RfC, USEPA, 2011	0.6 mg/m^3	2	e	<LOD (0.07)	<LOD (0.07)
Dichloropropane, 1,2-	RfC, USEPA, 1991	0.004 mg/m^3	0.01	c	<LOD (0.008)	<LOD (0.008)

Table 2 (continued)

Chemical	Exposure Guidance Values[a]		Corresponding BE Value, μg/L whole blood	Note	NER 2003-2004 Data, μg/L whole blood	
	Type, source, year	Value			GM	95%-ile
Hexachloroethane	RfC, USEPA, 2011	0.03 mg/m^3	0.2	e	<LOD (0.011)	<LOD (0.011)
Methyl-tert-butylether (MTBE)	RfC, USEPA, 1993	3 mg/m^3	20	c	0.011	0.17
Nitrobenzene	RfC, USEPA, 2009	0.009 mg/m^3	0.03	c	<LOD (0.3)	<LOD (0.3)
Tetrachloroethane, 1,1,2,2-	RfD, USEPA, 2010	0.02 mg/kg-d	0.2	e	<LOD (0.01)	<LOD (0.01)
Tetrachloroethylene (PCE)	RfD, USEPA, 1988	0.01 mg/kg-d	1	c	0.0422	0.14
Trichloroethane, 1,1,1-	RfC, USEPA, 2007	5 mg/m^3	20	c	<LOD (0.048)	<LOD (0.048)
Trichloroethane, 1,1,2-	RfD, USEPA, 1995	0004 mg/kg-d	0.05	c	<LOD (0.01)	<LOD (0.01)
Trichloroethylene	RfC, USEPA, 2011	0.002 mg/m^3	0.0062	e	<LOD (0.012)	<LOD (0.012)
Chloroform	RfD, USEPA, 2001	0.01 mg/kg-d	230 pg/ml	f	10[*] pg/ml	50 pg/ml
Bromodichloromethane	RfD, USEPA, 2005	0.02 mg/kg-d	80 pg/ml	f	1.4[*] pg/ml	9.5 pg/ml
Dibromochloromethane	RfD, USEPA, 2005	0.003 mg/kg-d	20 pg/ml	f	<LOD (0.6)[*] pg/ml	7.2 pg/ml
Bromoform	RfD, USEPA, 2005	0.03 mg/kg-d	130 pg/ml	f	<LOD (1.5)[*] pg/ml	6.4 pg/ml

GM: Geometric mean. RfC: reference concentration. RfD: reference dose. MRL: minimal risk level.

* Median

Notes: a: All USEPA exposure guidance values available at USEPA (2012a); ATSDR MRL available at ATSDR (2012).   b: Hays et al. (2012); c: Aylward et al. (2010b); d: Aylward et al. (2008a); e Reflects risk assessment value established since publication of Aylward et al. (2010b). Corresponding steady-state blood concentrations estimated using relationships between constant external exposures and blood concentrations from Table 2 of Aylward et al. (2010b). f: Aylward et al. (2008b)

Figure Legends

Figure 1: Hazard quotients (HQ) for NER analytes with available Biomonitoring

Equivalents (BEs) or other biomarker-based screening values, excluding VOCs (see

Figure 2 for VOCs); screening values and NHANES data reported in Table 1. Diamonds

represent HQ values at the geometric mean of the NHANES population data; squares

correspond to the 95th percentile. Open symbols correspond to the HQ at the limit of

detection (LOD) in cases where the analyte was not detected in the NHANES survey at

the specified quantile. For dioxin TEQ and PBDE 99, concentrations were not

quantifiable at the geometric mean, and variable LODs in the NHANES dataset prevent

selection of a single value to represent LOD. Deltamethrin was not detected at either the

geometric mean or the 95th percentile; the HQ associated with the LOD is indicated in the

figure.

Figure 2: Hazard quotients (HQs) for volatile organic compounds (VOCs) from the

NHANES 2003-2004 cycle for those VOCs with available BE values (see Table 2).

Diamonds represent HQ values at the geometric mean of the NHANES population data;

squares correspond to the 95th percentile. Open symbols correspond to the HQ at the

limit of detection in cases where the analyte was not detected in the NHANES survey at

the specified quantile.

Figure 3: Cancer risk estimates based on biomarker concentrations from the NER dataset

for those compounds with available cancer-based BE values. Diamonds represent cancer

risk values at the geometric mean of the NHANES population data; squares correspond to

the 95th percentile. Open symbols correspond to the risk level at the limit of detection in cases where the analyte was not detected in the NHANES survey at the specified quantile. All risk estimates assume that biomarker concentrations represent lifetime exposure levels. Cancer risk-based BE values are presented in Hays and Aylward 2008 (acrylamide); Aylward et al. 2010a (hexachlorobenzene); Kirman et al. 2011 (DDT); Hays et al. 2010 (arsenic), Hays et al. 2012 (benzene), and Aylward et al. 2008a (THMs).

Figure 4: Analytes by NHANES subsample from 2003-2004 cycle. Subsamples A, B, and C represent approximately 1/3rd samples of the full NHANES sample for a given cycle; the VOC subsample overlaps groups A, B, and C. Analytes were measured in blood or urine specimens from persons within the specified subsample and meeting the specified age cutoffs.

Figure 5: Box plots of hazard quotients for individual THM compounds and the hazard index for the combined THM hazard quotients calculated per equation 2. Box plots omit extreme values. The median is represented by a horizontal line, boxes represent the interquartile range, and lower and upper whiskers extend to 1.5 times the interquartile range below the 25th and above the 75th percentiles, respectively.

Figure 1
152x105mm (300 x 300 DPI)

Figure 2
122x85mm (200 x 200 DPI)

Figure 3
152x119mm (300 x 300 DPI)

Figure 4
152x93mm (300 x 300 DPI)

Figure 5
108x78mm (200 x 200 DPI)